A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

• Status: RECRUITING
• Trial end date: 2030-02-24

Summary

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:

• The safety of the study treatment and if people tolerate it.
• A safe dose level of I-DXd that can be used with other treatments.
• Participant levels of prostate specific antigen (PSA) during treatment.

• Phase: PHASE1

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Collaborator: Daiichi Sankyo
• Treatments: abiraterone; Docetaxel; enzalutamide